Glass J D, Selim M, Rea M A
Department of Biological Sciences, Kent State University, OH 44242.
Brain Res. 1994 Feb 28;638(1-2):235-42. doi: 10.1016/0006-8993(94)90655-6.
In previous studies, we showed that light-induced Fos protein expression in the ventrolateral SCN is markedly inhibited by the nonselective serotonergic, quipazine. The present experiments were undertaken to characterize the effects of various serotonin (5-HT) receptor ligands on photic signalling in the SCN. The extent of expression of light-induced Fos-like immunoreactivity (Fos-LI) in the SCN was used as a marker for this response. Exposure of hamsters to a light pulse delivered during the latter part of the dark phase (7 h after lights-off; LD 14:10) elicited an intense expression of Fos-LI in nuclei of cells situated principally in the ventrolateral region of the SCN. Pretreatment with an i.p. injection of the 5-HT1A receptor agonists, 8-OH-DPAT or buspirone, 30 min before the light pulse significantly inhibited the photic expression of Fos-LI (maximal suppression 45.7 +/- 8.1 and 43.0 +/- 1.3%, respectively, both P < 0.01 vs. vehicle controls). Treatment with the 5-HT1A receptor antagonist, NAN-190, administered 15 min before 8-OH-DPAT injection prevented the inhibitory effect of 8-OH-DPAT (100.9 +/- 6.0% vs. controls, P > 0.9). Pretreatment with the 5-HT1B receptor agonist, TFMPP, caused a small but significant suppression of Fos-LI (14.8 +/- 3.5% vs. controls, P < 0.05). In contrast to the significant 5-HT1 receptor agonist effects, pretreatment with 5-HT2 or 5-HT3 receptor agonists, alpha-methyl-5-HT and 1-phenylbiguanide had little suppressive effect on Fos-LI (7.9 +/- 2.1 and 13.0 +/- 5.0% suppression, respectively, both P > 0.1 vs. controls).(ABSTRACT TRUNCATED AT 250 WORDS)
在先前的研究中,我们发现非选择性血清素能药物喹哌嗪可显著抑制光诱导的腹外侧视交叉上核(SCN)中Fos蛋白的表达。本实验旨在研究各种血清素(5-羟色胺,5-HT)受体配体对SCN光信号传导的影响。SCN中光诱导的Fos样免疫反应性(Fos-LI)的表达程度被用作此反应的标志物。在暗期后期(熄灯后7小时;光照-黑暗周期为14:10)给仓鼠施加一个光脉冲,可在主要位于SCN腹外侧区域的细胞核中引发强烈的Fos-LI表达。在光脉冲前30分钟腹腔注射5-HT1A受体激动剂8-羟基二丙胺基四氢萘(8-OH-DPAT)或丁螺环酮进行预处理,可显著抑制Fos-LI的光诱导表达(最大抑制率分别为45.7±8.1%和43.0±1.3%,与溶剂对照组相比,P均<0.01)。在注射8-OH-DPAT前15分钟给予5-HT1A受体拮抗剂NAN-190进行处理,可阻止8-OH-DPAT的抑制作用(与对照组相比为100.9±6.0%,P>0.9)。用5-HT1B受体激动剂三氟甲基苯哌嗪(TFMPP)进行预处理,可导致Fos-LI有轻微但显著的抑制(与对照组相比为14.8±3.5%,P<0.05)。与5-HT1受体激动剂的显著作用相反,用5-HT2或5-HT3受体激动剂α-甲基-5-羟色胺和1-苯基双胍进行预处理,对Fos-LI的抑制作用很小(抑制率分别为7.9±2.1%和13.0±5.0%,与对照组相比,P均>0.1)。(摘要截断于250字)